Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial

Giovanni Addolorato, Fabio Caputo, Katrin Skala, Henriette Walter, Otto Lesch

Risultato della ricerca: Contributo in rivistaArticolo in rivista

17 Citazioni (Scopus)

Abstract

Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.
Lingua originaleEnglish
pagine (da-a)743-752
Numero di pagine10
RivistaCNS Drugs
Volume28
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • alcohol withdrawal syndrome
  • sodium oxybate

Fingerprint Entra nei temi di ricerca di 'Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial'. Insieme formano una fingerprint unica.

Cita questo